Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

Clinical trial NCT04251169 · TERMINATED

Trial details

NCT number: NCT04251169
Sponsor: SOLTI Breast Cancer Research Group
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2020-07-21
Primary completion: 2024-04-10
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.